FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average b	ourden							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Lawton Alison Frances</u>				2. Issuer Name <b>and</b> Ticker or Trading Symbol Magenta Therapeutics, Inc. [ MGTA ]						(Ch	eck all applic	10% Owner		ner		
(Last) (First) (Middle) C/O MAGENTA THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 12/22/2020							Officer below)	(give title		ther (spelow)	pecify
100 TECHNOLOGY SQUARE				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	IDGE M	ÍΑ	02139									X Form f	led by One led by More			
(City)	(S	tate)	(Zip)													
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			. Transactio ate Month/Day/\	Execution Date,		Code (Inst	Transaction Disposed Of (D) (Instr. 3, Code (Instr. 5)			Beneficia	s ally ollowing	6. Ownersl Form: Dire (D) or Indir (I) (Instr. 4)	ect E	7. Nature of Indirect Beneficial Ownership		
					Code V Amount (A) or (D)		Price	Transact (Instr. 3 a	ion(s)	"		nstr. 4)				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  3. Transaction Date (Month/Day/Year)  3. Transaction Date (Execution Date, if any (Month/Day/Year)		Code	ransaction of Code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$7.85	12/22/2020		A		36,377		(1)	12/21/2030	Common Stock	36,377	\$0.00	36,377		D	

## Explanation of Responses:

1. This option shall vest and become exercisable over three years, with 33% of this option vesting on December 22, 2021, and the remainder vesting in 24 equal monthly installments thereafter.

## Remarks:

/s/Zoran Zdraveski, Attorneyin-Fact for Alison Frances

12/23/2020

Lawton

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.